Health Condition 1: C15-C26- Malignant neoplasms of digestive organs
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: assd: ad
Control Intervention2: NIL: NIL
Sponsors
Rasayu Cancer Clinic Pune
Eligibility
Inclusion criteria
Inclusion criteria: 1 Histopathologically diagnosed Patients with gastrointestinal cancer which includes stomach colorectal pancreas esophagus Liver cancers etc 2 Male and Female patient above the age of 60 years 3 Patients who are ineligible to receive conventional anticancer therapy 4 Patients for whom no conventional anticancer therapy exist 5 Those that are willingly refusing conventional anticancer therapy with the reason known 6 Patients having resistance to conventional therapies like chemotherapy,immunotherapy etc 7.Patients who are willing to take exclusively Rasayana therapy
Exclusion criteria
Exclusion criteria: 1 Patients taking any other conventional or alternative treatment which is known to significantly impact Patients Quality of life 2 Patients receiving any conventional anticancer therapy 3 Patients with any psychiatric disturbance major depression psychosis which will impair Patients ability to respond the questions in QoL questionnaire 4 Patients with cerebral mets 5 Patients with taking analgesics 6 Patients with expected survival of less than 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of Rasayana therapy in improving health related QoL , Physical performance status and identify its impact on survivalTimepoint: Pre and post therapy- monthly Quality of life and physical performance status will be assessed by FACT G scale and ECOG measuring tool upto 3 months and patient will be observed for overall survival further upto 1 or more than 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the Safety and tolerability of Rasayana therapy To evaluate impact of Rasayana therapy on gastrointestinal tumorsTimepoint: Safety will be assessed at baseline and bimonthly with heamatological and biochemical parameters and by CTCAE V 5 criteria Tumour response will be assessed by Radiological assessment with PET-CT scan at baseline and post therapy at 6 months | — |
Countries
India
Contacts
Public ContactDr Yogesh Bendale
Rasayu Cancer Clinic Pune
Outcome results
None listed